Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

Part of paid clinical trials in Sacramento, California.

Sponsor
Cellenkos, Inc.
Study ID
NCT05423691
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Myelofibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CK0804 — DRUG
    CK0804 is a cryopreserved, allogeneic T-regulatory cell product that is manipulated to traffic to the bone marrow.

Study Details

To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib

Key Dates

Start date
Dec 27, 2022
Status verified
Apr 2025
Primary completion
Apr 30, 2026
Completion
Dec 30, 2026

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm 1
    CK0804 will be administered intravenously (IV) 100 million Treg Cells every 28 days up to 6 infusions.

Primary Outcome Measure

To determine Treatment limiting toxicity (TLT) as defined below [ Time Frame: 28 days ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
UC Davis HealthSacramentoCalifornia95817
Trisha Yassear, CCRC
[email protected]
916-718-2107
Mehrdad Abedi, MD (PRINCIPAL_INVESTIGATOR)
Columbia UniversityNew YorkNew York10032
Beatriz Raposo Corrandini, MSc
[email protected]
212-305-6679
Mark Heaney, MD (PRINCIPAL_INVESTIGATOR)
Montefiore Einstein Cancer CenterThe BronxNew York10461
Clinical Research Coordinator
Swati Goel, MD (PRINCIPAL_INVESTIGATOR)
The University of Texas MD Anderson Cancer CenterHoustonTexas77030
Alleyne Genevieve
[email protected]
713-792-4986
Lucia Masarova, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Sacramento, CA

By research site
UC Davis Health· Sacramento, CAColumbia University· New York, NYMontefiore Einstein Cancer Center· The Bronx, NYThe University of Texas MD Anderson Cancer Center· Houston, TX

Related Studies